Olanzapine-induced rhabdomyolysis

OBJECTIVE: To report a possible case of olanzapine-induced rhabdomyolysis w ith concomitant lithium-induced pseudo-infarction electrocardiogram changes . CASE SUMMARY: A 13-year-old white boy was admitted to the hospital with pro found weakness and electrocardiogram (ECG) changes suggestive of myocardial damage after starting olanzapine and lithium. An adverse medication effect was not considered at the time of the patient's admission. The time course of onset of weakness was coincident with administration of olanzapine. ECG abnormalities are a known manifestation of lithium therapy. DISCUSSION: This is a case description of olanzapine-induced rhabdomyolysis . Although other antipsychotic agents have been reported to cause rhabdomyo lysis, an adverse drug reaction was not initially part of this patient's di fferential diagnosis. The patient had begun reporting myalgias six days aft er starting olanzapine. Fourteen days later, these symptoms forced him to b ed rest; lithium was added for behavior misinterpreted as disobedience and oppositional disorder. Only when medications were considered as cause of th e weakness and ECG changes, was the true nature of the patient's illness di scovered. CONCLUSIONS: Olanzapine, like other neuroleptic agents, can cause rhabdomyo lysis. Lithium can cause multiple ECG changes that can be misinterpreted as myocardial damage. Medication effects and adverse effects must always be c onsidered in any disease complex.